Arvinas' ARV-102 Shows Promising Biomarker and Oculomotor Data in…

Event summary

Arvinas presented final Phase 1 trial data for ARV-102 at the 2026 International Congress of Parkinson’s Disease and Movement Disorders, showing dose-dependent improvements in ocular saccadic hypometria and reductions in LRRK2 biomarkers.
The trial involved 24 Parkinson’s patients treated with ARV-102 or placebo for 28 days, with doses ranging from 20 mg to 80 mg.
Key findings included associations between LRRK2 degradation and improvements in oculomotor function and synaptic biomarkers.
ARV-102 is an orally bioavailable PROTAC degrader designed to target LRRK2, a protein implicated in neurodegenerative diseases.

The big picture

Arvinas’ Phase 1 data for ARV-102 reinforces the potential of PROTAC degraders in targeting LRRK2, a key protein in neurodegenerative diseases. The findings support further exploration of ARV-102 as a therapeutic approach, though the path to regulatory approval remains long. The company’s ability to leverage this data in partnerships, such as its collaboration with Pfizer, will be critical in advancing its pipeline.

What we're watching

Clinical Validation: Whether ARV-102’s biomarker and oculomotor improvements translate into meaningful clinical efficacy in later-stage trials.
Development Pipeline: The pace at which Arvinas advances ARV-102 through further clinical development, particularly in neurodegenerative indications beyond Parkinson’s.
Competitive Positioning: How Arvinas differentiates ARV-102 in a landscape where LRRK2 inhibitors are also under investigation for Parkinson’s disease.